Cemil BİLİR, Ayla GÖKMEN, Hüseyin ENGİN, Serap TİLKİ ÜNAL, Yücel ÜSTÜNDAĞ

Plasma soluble thrombomodulin and soluble endothelial protein C receptor levels in colorectal cancer patients

Thrombomodulin (TM) and endothelial protein C receptor (EPCR) are 2 transmembrane proteins that are thought to play an important role in cancer. We aimed to discover whether these 2 proteins are prognostic indicators in colorectal cancer. Materials and methods: Plasma TM and EPCR levels were measured using the ELISA method in 50 patients in different tumor stages that had been recently diagnosed with colorectal cancer and in a healthy control group of 50 people. Results: In colorectal cancer patients, higher plasma TM (21.3 ± 22.8 ng/mL, 13.2 ± 16.2 ng/mL, P = 0.010) and plasma EPCR levels (149.9 ± 79.6, 113.3 ± 49.3, P = 0.007) were determined compared to the control group. No statistically significant relationship was present between plasma TM, EPCR levels and tumor stage, tumor localization, tumor differentiation, lymphovascular invasion state, microvascular thrombus existence, and thrombosis progression (P > 0.05). Conclusion: We think that these 2 proteins are released into plasma as an indicator of endothelial dysfunction and can play a role in pathogenesis and biology of colorectal cancer.

Anahtar Kelimeler:

Key words: Thrombomodulin, endothelial protein C receptor, colorectal cancer

Plasma soluble thrombomodulin and soluble endothelial protein C receptor levels in colorectal cancer patients

Keywords:

Key words: Thrombomodulin, endothelial protein C receptor, colorectal cancer,

PDF

___

Wojtukiewicz MZ, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 2007; 33: 621–42.
Şahin E, Şahin M, Gümüşlü S. The effect of KNK437, a heat shock protein inhibitor, on angiogenesis of endothelial cells. Turk J Med Sci 2012; 42: 597–604.
Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109–16.
Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000: 83; 639–43.
Lindahl AK, Boffa MC, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost 1993; 69: 112–
Barutçuoğlu B, Parıldar Z, Mutaf MI, Özmen D, Alioğlu E, Habif S et al. Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients. Turk J Med Sci 2010; 40: 239–48.
Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 2001; 85: 356–61.
Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 1995; 21: 1285–90. Kim SJ, Shiba E, Ishii H, Inoue T, Taguchi T, Tanji Y et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study. Anticancer Res 1997; 17: 2319–23.
Wilhelm S, Schmitt M, Parkinson J, Kuhn W, Graeff H, Wilhelm OG. Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. Int J Oncol 1998; 13: 645–51.
Tamura A, Hebisawa A, Hayashi K, Sagara Y, Fukushima K, Kurashima A et al. Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung. Lung Cancer 2001; 34: 375–82.
Ogawa H, Yonezawa S, Maruyama I, Matsushita Y, Tezuka Y, Toyoyama H et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 2000; 149: 95–103.
Hamatake M, Ishida T, Mitsudomi T, Akazawa K, Sugimachi K. Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res 1996; 2: 763–6.